Japan Earthquake Disrupts Auto and Chip Supply Chains 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SAN DIEGO, May 07, 2018 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 7194327
Prior to the webcast at approximately 4:30 PM Eastern Time on May 10, Cytori will issue its first quarter earnings release which will review Cytori’s first quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
[email protected]
